Inovio publishes Q2 2026 financial results presentation focusing on INO-3107 BLA review progress - INO News | RalliesInovio publishes Q2 2026 financial results presentation focusing on INO-3107 BLA review progress
I
INO• Pipeline update
- Pipeline update noted a positive Phase 3 readout in China for VGX-3100 in HPV 16/18+ cervical dysplasia from partner ApolloBio.
INO-3107 FDA review progress
- Inovio highlighted FDA review progress for INO-3107, citing a PDUFA target action date of Oct. 30, 2026.
- Late-cycle review completed. All scheduled FDA inspections conducted. Label negotiations anticipated in September 2026.
- FDA feedback on the design of a confirmatory trial is expected, following a July clinical informal meeting.
